Psoriatic Arthritis | Treatment Algorithms: Claims Data Analysis | US | 2024

Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S. market for conventional DMARD-refractory PsA has a wide array of effective treatments, including six TNF-α inhibitors, two IL-17 inhibitors, an IL-12/23 inhibitor, two IL-23 inhibitors, and three targeted oral agents (a PDE4 inhibitor and two JAK inhibitors). The launch of adalimumab biosimilars has also expanded physicians’ treatment choices for PsA, intensifying the competition in an already saturated market.

QUESTIONS ANSWERED

• What shares do key therapies and brands garner by line of therapy in newly diagnosed PsA patients?
• What are the quarterly trends in prescribing among recently treated and newly diagnosed PsA patients?
• How have Skyrizi and Rinvoq been integrated into the treatment algorithm, and what are their sources of business? What percentage of PsA patients receive drug therapy within two years of diagnosis, and how quickly?
• What percentage of patients progress to later lines of therapy within two years of diagnosis? What percentage of PsA patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: AbbVie, Amgen, Johnson & Johnson Innovative Medicine, Novartis, Eli Lilly, Pfizer, Sun Pharma, UCB

Key drugs: Humira, Enbrel, Remicade, biosimilar infliximab, Cimzia, Simponi, Simponi Aria, Stelara, Cosentyx, Taltz, Tremfya, Skyrizi, Orencia, Otezla, Xeljanz, Rinvoq, methotrexate

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.